Promore Pharma Plans to Expand Indications of Therapeutic Peptide PXL01 in the Field of Dermal Scarring
STOCKHOLM, 3 September, 2018 -- Promore Pharma AB, a Swedish biopharmaceutical developer of therapeutic peptides, today announced that the company plans to expand the indications of its lead compound, the anti-adhesion and anti-scarring agent PXL01, to explore the feasibility of using it for prevention of dermal scarring.PXL01 is currently in clinical Phase III development for the prevention of post-surgical adhesions after tendon repair surgery in the hand. Promore Pharma has now planned for a clinical Phase I/II study in the field of dermal scarring. The study will be performed in Sweden